Company news
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) news
Every Inhibikase Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
August 11, 2026
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
July 23, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility
July 15, 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
July 14, 2026
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
May 12, 2026
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonar...
April 7, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
April 6, 2026
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
March 26, 2026
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
November 20, 2025
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 20, 2025
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
November 20, 2025
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
November 14, 2025
Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer
August 19, 2025
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
August 15, 2025
Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity
August 14, 2025
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
May 14, 2025
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
April 14, 2025
Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity
March 27, 2025
Inhibikase Announces Expansion of Senior Leadership Team
February 24, 2025
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
February 18, 2025
Inhibikase Therapeutics : Market Offering Agreement Form 8 K
December 5, 2024
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
November 14, 2024
Inhibikase Therapeutics : Announces Closing of up to $275 Million Financing and Advancement of IkT 001Pro into a Late Stage Clinical Tria...
October 22, 2024
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial ...
October 21, 2024